Mayne Pharma Group Limited (ASX:MYX)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Dermatology	138.70M	154.09M	174.86M	56.99M	92.21M
Women's Health	174.27M	178.37M	142.83M	61.89M	10.57M
International	70.71M	75.64M	70.71M	64.70M	54.37M
Total	383.68M	408.10M	388.40M	183.59M	157.15M

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Australia and New Zealand	38.25M	41.94M	40.34M	41.20M	33.70M
United States	318.40M	338.85M	322.13M	124.46M	103.27M
Canada	15.42M	19.77M	13.37M	9.93M	9.06M
Europe and Other	6.61M	4.69M	7.13M	3.60M	6.25M
Asia	4.99M	2.85M	5.44M	4.40M	4.88M
Total	383.68M	408.10M	388.40M	183.59M	157.15M

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 1, 2026

Data Sources Report a data error